drugset / Trial / NCT04050709
QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase 1 study to assess the safety, preliminary efficacy of PD-L1 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with locally advanced or metastatic solid cancers.
Timeline
- Start
- 2019-07-18
- Primary completion
- 2021-03-30
- Completion
- 2026-03-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PD-L1 t-haNK | Cell therapy | — | — |